MCP
PCSA icon

Mirador Capital Partners’s Processa Pharmaceuticals PCSA Stock Holding History

Mirador Capital Partners’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-39
Closed -$4.88K – 197
2023
Q3 		$4.88K Buy
39
+1
+3% +$189 ﹤0.01% 185
2023
Q2 		$9.33K Sell
38
-3
-7% -$886 ﹤0.01% 189
2023
Q1 		$10.2K Sell
41
-2
-5% -$806 ﹤0.01% 188
2022
Q4 		$23.4K Buy
+43
New +$41.5K 0.01% 190

Other funds holding PCSA

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $1.81B AUM 17.83% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirador Capital Partners's PCSA Position: Q4 2023 in Review

Mirador Capital Partners sold out of Processa Pharmaceuticals (PCSA) in Q4 2023, closing a stake of 39 shares — an estimated $4.88K sold.

Mirador Capital Partners first reported a position in PCSA in Q4 2022 and held it in 4 quarters. The position peaked at $23.4K in Q4 2022. 18 funds tracked by Wall St. Rank hold PCSA as of Q4 2023.

  • Mirador Capital Partners reported no remaining Processa Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Mirador Capital Partners sold 39 Processa Pharmaceuticals shares in Q4 2023, an estimated $4.88K.
  • Mirador Capital Partners first reported a position in Processa Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Mirador Capital Partners's Processa Pharmaceuticals position peaked at $23.4K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2023.

Based on Mirador Capital Partners's 13F filing for Q4 2023, filed 19 Jan 2024.